95 related articles for article (PubMed ID: 20540065)
1. Structure-based virtual screening and electrophysiological evaluation of new chemotypes of K(v)1.5 channel blockers.
Yang Q; Fedida D; Xu H; Wang B; Du L; Wang X; Li M; You Q
ChemMedChem; 2010 Aug; 5(8):1353-8. PubMed ID: 20540065
[TBL] [Abstract][Full Text] [Related]
2. The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches.
Pirard B; Brendel J; Peukert S
J Chem Inf Model; 2005; 45(2):477-85. PubMed ID: 15807513
[TBL] [Abstract][Full Text] [Related]
3. Discovering potassium channel blockers from synthetic compound database by using structure-based virtual screening in conjunction with electrophysiological assay.
Liu H; Gao ZB; Yao Z; Zheng S; Li Y; Zhu W; Tan X; Luo X; Shen J; Chen K; Hu GY; Jiang H
J Med Chem; 2007 Jan; 50(1):83-93. PubMed ID: 17201412
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
[TBL] [Abstract][Full Text] [Related]
5. Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.
Lloyd J; Finlay HJ; Atwal K; Kover A; Prol J; Yan L; Bhandaru R; Vaccaro W; Huynh T; Huang CS; Conder M; Jenkins-West T; Sun H; Li D; Levesque P
Bioorg Med Chem Lett; 2009 Sep; 19(18):5469-73. PubMed ID: 19665893
[TBL] [Abstract][Full Text] [Related]
6. Modeling the binding modes of Kv1.5 potassium channel and blockers.
Yang Q; Du L; Wang X; Li M; You Q
J Mol Graph Model; 2008 Sep; 27(2):178-87. PubMed ID: 18485768
[TBL] [Abstract][Full Text] [Related]
7. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
[TBL] [Abstract][Full Text] [Related]
8. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
[TBL] [Abstract][Full Text] [Related]
9. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.
Gross MF; Beaudoin S; McNaughton-Smith G; Amato GS; Castle NA; Huang C; Zou A; Yu W
Bioorg Med Chem Lett; 2007 May; 17(10):2849-53. PubMed ID: 17350840
[TBL] [Abstract][Full Text] [Related]
10. Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels.
Eldstrom J; Fedida D
J Mol Graph Model; 2009 Oct; 28(3):226-35. PubMed ID: 19713139
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay.
Slack M; Kirchhoff C; Moller C; Winkler D; Netzer R
J Biomol Screen; 2006 Feb; 11(1):57-64. PubMed ID: 16314404
[TBL] [Abstract][Full Text] [Related]
12. Benzopyran sulfonamides as KV1.5 potassium channel blockers.
Lloyd J; Atwal KS; Finlay HJ; Nyman M; Huynh T; Bhandaru R; Kover A; Schmidt J; Vaccaro W; Conder ML; Jenkins-West T; Levesque P
Bioorg Med Chem Lett; 2007 Jun; 17(12):3271-5. PubMed ID: 17462888
[TBL] [Abstract][Full Text] [Related]
13. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.
Tamargo J; Caballero R; Gómez R; Delpón E
Expert Opin Investig Drugs; 2009 Apr; 18(4):399-416. PubMed ID: 19335273
[TBL] [Abstract][Full Text] [Related]
14. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
Peukert S; Brendel J; Pirard B; Brüggemann A; Below P; Kleemann HW; Hemmerle H; Schmidt W
J Med Chem; 2003 Feb; 46(4):486-98. PubMed ID: 12570371
[TBL] [Abstract][Full Text] [Related]
15. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.
Johnson JA; Xu N; Jeon Y; Finlay HJ; Kover A; Conder ML; Sun H; Li D; Levesque P; Hsueh MM; Harper TW; Wexler RR; Lloyd J
Bioorg Med Chem Lett; 2014 Jul; 24(14):3018-22. PubMed ID: 24881565
[TBL] [Abstract][Full Text] [Related]
17. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
18. Pseudosaccharin amines as potent and selective KV1.5 blockers.
Lloyd J; Finlay HJ; Kover A; Johnson J; Pi Z; Jiang J; Neels J; Cavallaro C; Wexler R; Conder ML; Shi H; Li D; Sun H; Chimalakonda A; Huang C; Salvati M; Levesque P
Bioorg Med Chem Lett; 2015 Nov; 25(21):4983-4986. PubMed ID: 25801931
[TBL] [Abstract][Full Text] [Related]
19. Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.
Nanda KK; Nolt MB; Cato MJ; Kane SA; Kiss L; Spencer RH; Wang J; Lynch JJ; Regan CP; Stump GL; Li B; White R; Yeh S; Bogusky MJ; Bilodeau MT; Dinsmore CJ; Lindsley CW; Hartman GD; Wolkenberg SE; Trotter BW
Bioorg Med Chem Lett; 2006 Nov; 16(22):5897-901. PubMed ID: 16949818
[TBL] [Abstract][Full Text] [Related]
20. Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors.
Guo X; Yang Q; Xu J; Zhang L; Chu H; Yu P; Zhu Y; Wei J; Chen W; Zhang Y; Zhang X; Sun H; Tang Y; You Q
Bioorg Med Chem; 2013 Nov; 21(21):6466-76. PubMed ID: 24071446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
